IMU-838, a Developmental DHODH Inhibitor in Phase II for Autoimmune Disease, Shows Anti-SARS-CoV-2 and Broad-Spectrum Antiviral Efficacy In Vitro

The ongoing pandemic spread of the severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2) demands skillful strategies for novel drug development, drug repurposing and cotreatments, in particular focusing on existing candidates of host-directed antivirals (HDAs). The developmental drug IMU...

Descripción completa

Detalles Bibliográficos
Autores principales: Hahn, Friedrich, Wangen, Christina, Häge, Sigrun, Peter, Antonia Sophia, Dobler, Gerhard, Hurst, Brett, Julander, Justin, Fuchs, Jonas, Ruzsics, Zsolt, Überla, Klaus, Jäck, Hans-Martin, Ptak, Roger, Muehler, Andreas, Gröppel, Manfred, Vitt, Daniel, Peelen, Evelyn, Kohlhof, Hella, Marschall, Manfred
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7762174/
https://www.ncbi.nlm.nih.gov/pubmed/33291455
http://dx.doi.org/10.3390/v12121394

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7762174/
https://www.ncbi.nlm.nih.gov/pubmed/33291455
http://dx.doi.org/10.3390/v12121394

Ejemplares similares